Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
Programmed Death Ligand 1 (PD-L1) positivity rates differ between different metastatic sites and the primary tumor. Understanding PD-L1 expression characteristics could guide biopsy procedures and motivate research to better understand site-specific differences in the tumor microenvironment. The pur...
Main Authors: | Brian Alexander, Lajos Pusztai, David L Rimm, Priti Hegde, Mariya Rozenblit, Richard Huang, Natalie Danziger, Shakti Ramkissoon, Kim Blenman, Jeffrey S Ross |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e001558.full |
Similar Items
-
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
by: Brian Alexander, et al.
Published: (2020-07-01) -
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
by: Mariya Rozenblit, et al.
Published: (2021-01-01) -
Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
by: Lajos Pusztai, et al.
Published: (2021-04-01) -
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer
by: David L. Rimm, et al.
Published: (2019-06-01) -
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
by: Michael T. Barrett, et al.
Published: (2018-07-01)